Enasidenib Mesylate

For research use only.

Catalog No.S4929 Synonyms: Idhifa, AG-221 mesylate

Enasidenib Mesylate Chemical Structure

CAS No. 1650550-25-6

Enasidenib (Idhifa, AG-221) mesylate is an orally available, selective and potent inhibitor of mutant isocitrate dehydrogenase 2 (IDH2).

Purity & Quality Control

Choose Selective Dehydrogenase Inhibitors

Biological Activity

Description Enasidenib (Idhifa, AG-221) mesylate is an orally available, selective and potent inhibitor of mutant isocitrate dehydrogenase 2 (IDH2).
Targets
IDH2 [1]
()

Protocol

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.59 mM)
Water Insoluble
Ethanol '''10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 569.48
Formula

C20H21F6N7O4S

CAS No. 1650550-25-6
Storage powder
in solvent
Synonyms Idhifa, AG-221 mesylate

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04955938 Not yet recruiting Drug: Ivosidenib|Drug: Enasidenib|Drug: Fedratinib IDH Mutation|IDH1 Mutation|IDH2 Gene Mutation|Blood Cancer|Myeloproliferative Neoplasm University of Chicago October 1 2021 Phase 1
NCT04203316 Recruiting Drug: Enasidenib|Drug: Enasidenib Mesylate Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia Children''s Oncology Group|National Cancer Institute (NCI) March 30 2020 Phase 2
NCT03515512 Active not recruiting Drug: Enasidenib Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia Massachusetts General Hospital|Celgene July 17 2018 Phase 1
NCT02273739 Completed Drug: Enasidenib Solid Tumor|Glioma|Angioimmunoblastic T-cell Lymphoma|Intrahepatic Cholangiocarcinoma|Chondrosarcoma Celgene|Celgene Corporation December 8 2014 Phase 1|Phase 2
NCT02218346 Completed Drug: AG221 Healthy Volunteers Agios Pharmaceuticals Inc.|Celgene Corporation August 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Dehydrogenase Signaling Pathway Map

Related Dehydrogenase Products

Tags: buy Enasidenib Mesylate | Enasidenib Mesylate supplier | purchase Enasidenib Mesylate | Enasidenib Mesylate cost | Enasidenib Mesylate manufacturer | order Enasidenib Mesylate | Enasidenib Mesylate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID